Last $5.19 USD
Change Today -0.02 / -0.38%
Volume 45.2K
MDGN On Other Exchanges
Symbol
Exchange
NYSE Amex
As of 5:15 PM 12/24/14 All times are local (Market data is delayed by at least 15 minutes).

medgenics inc - unrestricted (MDGN) Key Developments

Medgenics Seeks Acquisitions

Medgenics, Inc. (AMEX:MDGN) has completed a Follow-on Equity Offering in the amount of $21.01 million. Medgenics said, "We intend to use the net proceeds from this offering for product development activities, including clinical trials for our most advanced product candidates and investigation of new applications for our technologies; for patent maintenance fees and intellectual property support; for licensing and research collaborations, including the research collaboration with the Children’s Hospital of Philadelphia; and for general corporate purposes and working capital, which may include the acquisitions or licensing of complementary technologies, products or businesses."

Medgenics, Inc. Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-03-2014 12:00 PM

Medgenics, Inc. Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-03-2014 12:00 PM. Venue: The New York Palace Hotel, 455 Madison Ave, New York, NY 10022, United States. Speakers: Michael F. Cola, Chief Executive Officer, President and Director.

Medgenics Signs Research Collaboration with The Children's Hospital of Philadelphia

Medgenics has entered into a research collaboration with The Children's Hospital of Philadelphia. The partnership is aimed at paediatric rare and orphan genetic diseases and at accelerating the development of transformational new therapies for these underserved patients. The biobank at Children's Hospital of Philadelphia's Center for Applied Genomics has the larger biorepositories of paediatric genetic data in the world. Access to the genetic information in the CAG biobank is intended to enable researchers at both firms to work rapidly and efficiently to identify new rare and orphan disease targets and accelerate the development of novel therapies into clinical stage programs. Under the contract, Medgenics will pay USD 5 million to The Children's Hospital of Philadelphia and will also have a license to use the rare and orphan disease samples at the CAG biobank for the purpose of developing and commercialising therapeutic treatments and diagnostic targets for rare and orphan diseases.

Medgenics, Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

Medgenics, Inc. announced unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported operating loss of $3,870,000 compared to $4,904,000 a year ago. Loss before taxes on income was $3,038,000 compared to $6,143,000 a year ago. Loss was $3,040,000 compared to $6,143,000 a year ago. Diluted loss per share was $0.21 compared to $0.33 a year ago. For the nine months, the company reported operating loss of $12,742,000 compared to $11,924,000 a year ago. Loss before taxes on income was $12,229,000 compared to $11,916,000 a year ago. Loss was $12,237,000 compared to $11,921,000 a year ago. Diluted loss per share was $0.68 compared to $0.68 a year ago.

Medgenics, Inc. to Present Initial Clinical Data from MDGN-201 Study at European Society of Gene and Cell Therapy Congress

Medgenics, Inc. announced that initial data from its ongoing Phase 1/2 clinical trial of MDGN-201, formerly known as EPODURE, will be presented at the 22nd Annual Congress of the European Society of Gene and Cell Therapy being held in The Hague, Netherlands from October 23, 2014 to October 26, 2014. The presentation entitled Prolonged Secretion of Physiological Levels of Autologous EPO by TARGT, will be presented by Dr. Garry Neil, Chief Scientific Officer. Dr. Neil will present data on the first three erythropoietin (EPO)-dependent patients from the ongoing clinical study of the TARGTsystem in dialysis patients with anemia due to end-stage renal disease or chronic kidney disease.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MDGN:US $5.19 USD -0.02

MDGN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for MDGN.
View Industry Companies
 

Industry Analysis

MDGN

Industry Average

Valuation MDGN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 8.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEDGENICS INC - UNRESTRICTED, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.